CSPC Innovation Pharmaceutical Co., Ltd. (SHE:300765)
30.16
-1.49 (-4.71%)
Mar 20, 2026, 3:04 PM CST
SHE:300765 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 772.17 | 872.08 | 3,770 | 2,196 | 1,244 |
Short-Term Investments | 208.35 | 355.53 | - | - | - |
Trading Asset Securities | 385.39 | 470.09 | - | - | 413.59 |
Cash & Short-Term Investments | 1,366 | 1,698 | 3,770 | 2,196 | 1,658 |
Cash Growth | -19.54% | -54.97% | 71.71% | 32.43% | 13.51% |
Accounts Receivable | 693.47 | 559.76 | 560.78 | 716.75 | 508.94 |
Other Receivables | 10.69 | 2.05 | 1.55 | 1.56 | 1.37 |
Receivables | 704.16 | 561.81 | 562.32 | 718.31 | 510.31 |
Inventory | 497.8 | 398.67 | 224.82 | 238.13 | 262 |
Other Current Assets | 285.28 | 144.22 | 60.29 | 38.47 | 56.92 |
Total Current Assets | 2,853 | 2,802 | 4,618 | 3,191 | 2,487 |
Property, Plant & Equipment | 2,800 | 2,668 | 2,312 | 1,055 | 926.42 |
Long-Term Investments | 259.22 | 264.45 | 267.07 | 253.49 | 243.19 |
Other Intangible Assets | 218.85 | 225.21 | 231.59 | 50.42 | 52.81 |
Long-Term Deferred Tax Assets | 21.83 | 21.61 | 17.36 | 18.88 | 12.5 |
Other Long-Term Assets | 123.03 | 40.29 | 26.33 | 15.9 | 19.06 |
Total Assets | 6,276 | 6,022 | 7,472 | 4,584 | 3,741 |
Accounts Payable | 721.62 | 396.21 | 1,264 | 178.75 | 129.17 |
Accrued Expenses | 58.12 | 32.22 | 66.11 | 66.24 | 54.57 |
Short-Term Debt | 3.2 | - | - | - | - |
Current Portion of Long-Term Debt | - | - | - | 0.22 | - |
Current Portion of Leases | 0.79 | 0.84 | 0.81 | - | 0.84 |
Current Income Taxes Payable | 7.3 | 17.15 | 28.36 | 34.77 | 14.95 |
Current Unearned Revenue | 26.09 | 18.68 | 19.8 | 68.26 | 30.37 |
Other Current Liabilities | 1,892 | 969.18 | 524.42 | 234.52 | 178.75 |
Total Current Liabilities | 2,709 | 1,434 | 1,904 | 582.77 | 408.64 |
Long-Term Debt | - | - | - | 19.8 | - |
Long-Term Leases | 1.66 | - | 0.84 | - | - |
Long-Term Unearned Revenue | 239.92 | 90.49 | 84.16 | 37.21 | 34.27 |
Long-Term Deferred Tax Liabilities | 1.87 | 1.4 | 0.02 | 0.06 | 0.67 |
Other Long-Term Liabilities | 528.46 | - | - | - | - |
Total Liabilities | 3,481 | 1,526 | 1,989 | 639.84 | 443.58 |
Common Stock | 1,405 | 1,405 | 1,171 | 618.93 | 546 |
Additional Paid-In Capital | 181.28 | 977.27 | 2,125 | 1,138 | 1,211 |
Retained Earnings | 1,398 | 1,667 | 1,988 | 2,177 | 1,533 |
Treasury Stock | -321.03 | -321.03 | -4.25 | - | - |
Comprehensive Income & Other | 4.26 | 2.5 | 1.98 | 0.72 | -1.2 |
Total Common Equity | 2,667 | 3,731 | 5,281 | 3,936 | 3,289 |
Minority Interest | 127.92 | 765.39 | 202.45 | 8.59 | 8.26 |
Shareholders' Equity | 2,795 | 4,496 | 5,483 | 3,944 | 3,298 |
Total Liabilities & Equity | 6,276 | 6,022 | 7,472 | 4,584 | 3,741 |
Total Debt | 5.65 | 0.84 | 1.65 | 20.02 | 0.84 |
Net Cash (Debt) | 1,360 | 1,697 | 3,769 | 2,176 | 1,657 |
Net Cash Growth | -19.84% | -54.97% | 73.21% | 31.29% | 13.45% |
Net Cash Per Share | 0.98 | 1.21 | 2.70 | 1.63 | 1.24 |
Filing Date Shares Outstanding | 1,393 | 1,393 | 1,405 | 1,337 | 1,179 |
Total Common Shares Outstanding | 1,393 | 1,393 | 1,405 | 1,337 | 1,179 |
Working Capital | 144.01 | 1,368 | 2,714 | 2,608 | 2,079 |
Book Value Per Share | 1.92 | 2.68 | 3.76 | 2.94 | 2.79 |
Tangible Book Value | 2,448 | 3,505 | 5,049 | 3,885 | 3,237 |
Tangible Book Value Per Share | 1.76 | 2.52 | 3.59 | 2.91 | 2.74 |
Buildings | 1,188 | 1,020 | 973.56 | 609.24 | 430.75 |
Machinery | 2,027 | 1,939 | 1,821 | 925.79 | 701.65 |
Construction In Progress | 681.25 | 620.23 | 228.71 | 70.74 | 294.97 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.